Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 90

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 90
---
 the third column, which are the shares to be sold in this offering, consist of the shares of Common Stock issuable upon exercise of the Advisor Warrants. WallachBeth Capital, LLC and its designees acquired the Advisor Warrants in the ordinary course of business and, at the time the Advisor Warrants were acquired, WallachBeth Capital, LLC nor its designees had any agreement or understanding, directly or indirectly, with any person to distribute such securities. |

| 42 |

<div align='center'>MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY</div>

Market Information

Our Common Stock is currently listed on the Nasdaq
Capital Market under the symbol “BIAF.” Our Tradeable Warrants are currently listed on the Nasdaq Capital Market under the
symbol “BIAWF.” The last reported sale price of our Common Stock and Tradeable Warrants on Nasdaq on April 9, 2025 was $0.63
per share of Common Stock and $0.14 per Tradeable Warrant.

Holders of Record

As of April 10, 2025, there were approximately 92
holders of record of shares of our Common Stock. This number does not reflect the beneficial holders of our Common Stock who hold shares
in street name through brokerage accounts or other nominees.

Dividends

We have never declared or paid any cash dividends
on our capital stock. We intend to retain all available funds and future earnings, if any, to fund the development and expansion of our
business, and we do not anticipate declaring or paying any cash dividends in the foreseeable future. Any future determination regarding
the declaration and payment of dividends, if any, will be at the discretion of our Board of Directors and will depend on then-existing
conditions, including our financial condition, results of operations, contractual restrictions, capital requirements, business prospects,
and other factors our Board of Directors may deem relevant.

| 43 |

<div align='center'>MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS</div>

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing at the end of this prospectus. Some of the information contained in this discussion and analysis is set forth at the end of this prospectus, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including